image Follow Us:

Respiratio 2019; 9 (1-2): 145-149

EPIDEMIOLOŠKE I KLINIČKE KARAKTERISTIKE CISTIČNE FIBROZEU ODRASLOJ DOBI

Olivera Ljuboja, Dragana Malčić Zanić

Review Article

Revijalni članak

doi: 10.26601/rsp.aprs.19.10

Sažetak
Danas zahvaljujući identifikaciji mutacija koje dovode do cistične fibroze, nastanka bolesti,
omogućeno je istraživanje o povezanosti vrsta mutacije (genotip) i njihove kliničke ekspresije (fenotip)
kod oboljelih. Uprkos dijagnostičkim kriterijima, dijagnoza CF-a nije uvijek laka, pogotovo u odrasloj
dobi kad se bolest može prezentovati varijabilnim fenotipom. Danas djeca rođena sa cističnom fibrozom
doživljavaju odraslu dob, sa očekivanom medijanom preživljavanja od 50 godina. Produžavanje životnog
vijeka u odraslu dob suočava bolesnike s novim terapijskim potrebama, a doktore s novim
prezentacijama i komplikacijama bolesti. Sa prelaskom bolesnika iz dječije u odraslu dob javljaju se
nova klinička stanja i komplikacije bolesti koje zahtijevaju poseban oblik zbrinjavanja i pružanja
specifične zdravstvene njege koju više nije moguće pružiti u postojećem pedijatrijskom okruženju. Tada
govorimo o procesu tranzicije ili prelaska bolesnika iz pedijatrijske u adultnu brigu. Tranzicija je
multidisciplinarni i aktivni proces za bolesnika veoma stresan te je neophodo posvetiti veliku pažnju
psihosocijalnim i obrazovnim potrebama mladog bolesnika.

Ključne riječi: cistična fibroza, odrasli bolesnici

Full Article (PDF)

Literatura

1. CFGCA (Cystic Fibrosis Genetics Analysis Consortium). The CFTR Mutation Database. Dostupno na: http://www3.genet.sickkids.on.ca/cftr/app

 

2. Do.Tješić-Drnković, L.Omerza,Du.Tješić-Drinković, S.Kelečić, D.Čaleta. Osobitosti cistične fibroze u adolescentnoj i odrasloj dobi. Pediatr. Croat. 2014; 58(1):66-71.

 

 

3. Cystic Fibrosis Foundation Patient Registry Annual Data Report. Cystic Fibrosis Foundation: 2008 Bethesda, USA.

 

 

4. Stephenson AL, Tom M, Berthiaume Y, et al. A contemporary survival analysis of individuals with cystic fibrosis: a cohort study. Eur Respir J. 2015; 45:670-679.

[CrossRef]
PMid:25395034

 

 

5. Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H, Drevinek P, Gulmans V, Krivec U, Olesen H; ECFS Patient Registry Steering Group. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry.

 

 

6. Eur Respir J. 2014; 43(1):125-33.

 

 

7. Flume PA. Pulmonary complications of cystic fibrosis. Respir Care. 2009; 54(5):618-27.

[CrossRef]
PMid:19393106

 

 

8. Eckles M, Anderson P. Cor pulmonale in cystic fibrosis. Semin Respir Crit Care Med. 2003; 24(3):323-30.

[CrossRef]
PMid:16088553

 

 

9. Hadjiliadis D. Special considerations for patients with cystic fi brosis undergoing lung transplantation. Chest. 2007;131:1224-31.

[CrossRef]
PMid:17426231

 

 

10. De Boeck K, Weren M, Proesmans M, Kerem E. Pancreatitis among patients with cystic fibrosis:correlation with pancreatic status and genotype. Pediatrics. 2005;115:463-9.

[CrossRef]
PMid:15772171

 

 

11. Noone PG. Zhou Z. Silverman LM. Jowell PS. Knowles MR. Cohn JA. Cystic fibrosis gene mutations and pancreatitis risk: relation to epithelial ion transport and trypsin inhibitor gene mutations. Gastroenterology. 2001; 121:1310-9.

[CrossRef]
PMid:11729110

 

 

12. Jay F., Chee Y. Ooi Pancreatitis and pancreatic cystosis in Cystic Fibrosis. Journal of Cystic Fibrosis. 2017; S79-S86.

[CrossRef]
PMid:28986028

 

 

13. Chan CL, Vigers T, Pyle L, Zeitler PS, Sagel SD, Nadeau KJ. Continues glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline. J Cyst Fibros. 2018; 17(6):783-790.

[CrossRef]
PMid:29580828

 

 

14. Mathiesen IH, Pressler T, Oturai P, KatzensteinTL, Skov M, Frikke-Schmidt R, Hitz MF.Osteoporosis Is Associated with Deteriorating Clinical Status in Adultswith Cystic Fibrosis. Int J Endocrinol. 2018.

[CrossRef]
PMid:29780417 PMCid:PMC5892249

 

 

15. Stalvey MS, Clines GA. Cystic Fibrosis-Related Bone Disease: Insights Into a Growing Problem. Curr Opin Endocrinol Diabetes Obes. 2013; 20(6): 547-552.

[CrossRef]
PMid:24468756 PMCid:PMC4061713

 

 

16. Abdul-Karim FW, King TA, Dahms BB, Gauderer MW, Boat TF. Carcinoma of extrahepatic biliary system in an adult with cystic fibrosis. Gastroenterology. 1982;82(4):758-762.

[CrossRef]

 

 

17. Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer Risk in Cystic Fibrosis: A 20-Year Nationwide Study From the United States. J Natl Cancer Inst 2013;105:122-129.

[CrossRef]
PMid:23178438

 

 

18. Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, and Lowenfels AB; On behalf of the Cystic Fibrosis Colorectal Cancer Screening Task Force Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations. Gastroenterology 2018;154:736-745.

[CrossRef]
PMid:29289528

 

 

19. Gini A, Zauber AG, Cenin DR, Omidvari AH, Hempstead SE, Fink AK, Lowenfels AB, Lansdorp-Vogelaar I. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. Gastroenterology. 2018;154(3):556-567.

[CrossRef]
PMid:29102616 PMCid:PMC5823285

 

 

20. Niccum DE, Billings JL, Dunitz JM, Khoruts A. Colonoscopic screening shows increased early incidence and progression of adenomas in cystic fibrosis. J Cyst Fibros. 2016;15(4):548-53.

[CrossRef]
PMid:26851188 PMCid:PMC5920645

 

 

21. J Geake. Pregnancy and cystic fibrosis: Approach to contemporary management. Obstet Med. 2014. 7(4):147-155.

[CrossRef]
PMid:27512443 PMCid:PMC4934991

 

Mr sci dr Olivera Ljuboja
pedijatar pulmolog
Tel: +387/51/342-429
Mobtel +387/65/527098
E mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Travel Turne Tranzito